Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYRWF Ayr Wellness	$0.03 -4.9%	$0.13	$0.00 ▼ $2.60	$4M	1.71	2.61 million shs	983,319 shs
COCP Cocrystal Pharma	$1.57 +3.9%	$1.61	$1.12 ▼ $3.26	$15.46M	2.07	169,877 shs	37,870 shs
EDSA Edesa Biotech	$2.40 +0.8%	$2.19	$1.55 ▼ $5.00	$16.75M	0.27	20,798 shs	27,900 shs
MTEX Mannatech	$8.52 +0.2%	$8.68	$7.05 ▼ $16.49	$16.16M	0.84	21,327 shs	6,051 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYRWF Ayr Wellness	-8.73%	+11.29%	-82.75%	-85.06%	-98.19%
COCP Cocrystal Pharma	-0.86%	-10.30%	-5.82%	+3.21%	-21.10%
EDSA Edesa Biotech	+0.85%	+5.31%	-2.06%	+21.43%	-45.91%
MTEX Mannatech	+2.97%	-14.14%	+2.04%	-13.71%	+21.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYRWF Ayr Wellness	2.8646 of 5 stars	3.3	4.0	2.8	0.0	1.3
COCP Cocrystal Pharma	3.1104 of 5 stars	3.5	5.0	2.7	1.7	0.0
EDSA Edesa Biotech	1.6095 of 5 stars	2.0	5.0	0.7	1.7	0.6
MTEX Mannatech	0.4434 of 5 stars	0.0	3.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYRWF Ayr Wellness	2.50	Moderate Buy	$3.00	9,046.34% Upside
COCP Cocrystal Pharma	3.00	Buy	$6.00	283.39% Upside
EDSA Edesa Biotech	4.00	Strong Buy	$5.00	108.33% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AYRWF, MTEX, COCP, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/27/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$5.00
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYRWF Ayr Wellness	$463.63M	0.01	N/A	N/A	$3.14 per share	0.01
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.70 per share	N/A
MTEX Mannatech	$117.87M	0.14	$2.14 per share	3.98	$3.14 per share	2.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYRWF Ayr Wellness	-$359.31M	-$3.26	N/A	N/A	N/A	-77.50%	-31.73%	-11.73%	N/A
COCP Cocrystal Pharma	-$17.50M	-$1.24	N/A	N/A	N/A	N/A	-144.12%	-102.85%	N/A
EDSA Edesa Biotech	-$6.17M	-$1.32	N/A	N/A	N/A	N/A	-162.95%	-60.33%	N/A
MTEX Mannatech	$2.49M	-$2.04	N/A	∞	N/A	-3.46%	-48.60%	-10.70%	11/10/2025 (Estimated)

Latest AYRWF, MTEX, COCP, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/12/2025	Q2 2025	MTEX Mannatech	N/A	-$2.27	N/A	-$2.27	N/A	$25.68 million
8/8/2025	Q3 2025	EDSA Edesa Biotech	-$0.26	-$0.25	+$0.01	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYRWF Ayr Wellness	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYRWF Ayr Wellness	1.10	1.60	0.57
COCP Cocrystal Pharma	N/A	3.69	4.57
EDSA Edesa Biotech	N/A	18.96	18.96
MTEX Mannatech	0.58	1.11	0.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYRWF Ayr Wellness	0.91%
COCP Cocrystal Pharma	6.72%
EDSA Edesa Biotech	5.50%
MTEX Mannatech	12.98%

Insider Ownership

Company	Insider Ownership
AYRWF Ayr Wellness	8.10%
COCP Cocrystal Pharma	28.14%
EDSA Edesa Biotech	22.60%
MTEX Mannatech	41.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYRWF Ayr Wellness	2,440	116.18 million	106.77 million	Not Optionable
COCP Cocrystal Pharma	10	10.26 million	7.37 million	Not Optionable
EDSA Edesa Biotech	20	7.04 million	5.45 million	Not Optionable
MTEX Mannatech	250	1.90 million	1.11 million	Not Optionable

AYRWF, MTEX, COCP, and EDSA Headlines

Recent News About These Companies

Mannatech trading halted, volatility trading pause

August 14, 2025 | msn.com

Mannatech Reports Financial Results for Second Quarter 2025

August 12, 2025 | businesswire.com

Mannatech, Incorporated (MTEX) - Yahoo Finance

July 24, 2025 | finance.yahoo.com

Mannatech names Peter Griscom as new chief operating officer

June 27, 2025 | investing.com

Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer - Morningstar

June 27, 2025 | morningstar.comM

Mannatech appoints Peter Griscom COO

June 26, 2025 | msn.com

Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

June 26, 2025 | businesswire.com

Mannatech Announces Results of Annual Shareholders’ Meeting

June 5, 2025 | finance.yahoo.com

Mannatech Announces Results of Annual Shareholders' Meeting

June 5, 2025 | businesswire.com

Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

May 21, 2025 | businesswire.com

Mannatech Reports Financial Results for First Quarter 2025

May 13, 2025 | businesswire.com

Astronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancements

April 14, 2025 | msn.com

Mannatech Reports Fourth Quarter 2024 Financial Results

March 26, 2025 | businesswire.com

Mannatech Stock Soars to 52-Week High, Hits $16 Mark

January 30, 2025 | msn.com

Mannatech names Robert Toth vice chairman of the board

November 27, 2024 | markets.businessinsider.com

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

November 26, 2024 | businesswire.com

Mannatech Inc. Q3 Earnings Summary

November 13, 2024 | markets.businessinsider.com

Mannatech Reports Financial Results for Third Quarter 2024

November 12, 2024 | businesswire.com

Trading (MTEX) With Integrated Risk Controls

October 17, 2024 | news.stocktradersdaily.comN

(MTEX) Investment Analysis

October 6, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYRWF, MTEX, COCP, and EDSA Company Descriptions

Ayr Wellness OTCMKTS:AYRWF

$0.03 0.00 (-4.93%)

As of 03:56 PM Eastern

Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.

Cocrystal Pharma NASDAQ:COCP

$1.56 +0.06 (+3.86%)

Closing price 03:48 PM Eastern

Extended Trading

$1.56 0.00 (-0.32%)

As of 05:57 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Edesa Biotech NASDAQ:EDSA

$2.40 +0.02 (+0.84%)

Closing price 03:51 PM Eastern

Extended Trading

$2.28 -0.12 (-5.17%)

As of 07:00 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Mannatech NASDAQ:MTEX

$8.52 +0.02 (+0.18%)

Closing price 03:45 PM Eastern

Extended Trading

$8.48 -0.04 (-0.47%)

As of 04:38 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time